Effects of exercise prescribed at different levels of claudication pain on walking performance in patients with intermittent claudication: a protocol for a randomised controlled trial.

Birkett, ST ORCID: https://orcid.org/0000-0003-0422-6843, Sinclair, J, Seed, SA, Pymer, S, Caldow, EJ ORCID: https://orcid.org/0000-0002-8466-7157, Ingle, L, Harwood, AE and Egun, A 2022, 'Effects of exercise prescribed at different levels of claudication pain on walking performance in patients with intermittent claudication: a protocol for a randomised controlled trial.' , Therapeutic advances in cardiovascular disease, 16 .

[img]
Preview
PDF - Published Version
Available under License Creative Commons Attribution 4.0.

Download (383kB) | Preview

Abstract

Peripheral artery disease affects over 236 million people globally and the classic symptom is intermittent claudication (IC) which is associated with reduction in physical activity. The evidence that supervised exercise programmes (SEPs) improve pain-free and maximal walking distance is irrefutable. However, adherence rates are low with exercise-related pain cited as a contributing factor. National and international guidelines recommend exercising at a moderate to maximal level of claudication pain to improve walking ability; however, exercising pain-free or at mild claudication pain has been shown to achieve this outcome. There is limited evidence that compares the relative effects of exercise prescribed at different levels of claudication pain. The objective of this study is to directly compare the effects of exercise prescribed at three different levels of claudication pain on walking performance. This study will be a single-centre randomised controlled trial. Based on an power calculation, 51 patients with IC will be allocated to 24 weeks of twice-weekly pain-free (PF), moderate pain (MOD-P) or maximal pain (MAX-P) exercise. The PF group will cease exercise at the onset of claudication (1 on the 0-4 IC rating scale), the MOD-P group will stop once moderate pain is reached (2 on the rating scale) and the MAX-P group will stop once maximal pain is reached (4 on the rating scale). Outcome measures will be assessed at baseline, 12 and 24 weeks adopting an analysis of covariance (ANCOVA) to compare MWD across three time points. The primary outcome for the trial will be change in maximal treadmill walking distance at 12 and 24 weeks. Trial registration number: NCT04370327.

Item Type: Article
Schools: Schools > School of Health and Society
Journal or Publication Title: Therapeutic advances in cardiovascular disease
Publisher: SAGE Publications
ISSN: 1753-9447
SWORD Depositor: Publications Router
Depositing User: Publications Router
Date Deposited: 11 Aug 2022 13:52
Last Modified: 17 Aug 2022 08:03
URI: https://usir.salford.ac.uk/id/eprint/64397

Actions (login required)

Edit record (repository staff only) Edit record (repository staff only)

Downloads

Downloads per month over past year